



Achalasia & POEM (Peroral endoscopic myotomy)

Fellow. 신인섭

Division of Gastroenterology, Department of Medicine
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,
Korea

Contents

- Definition
- Epidemiology
- Etiology
- Pathophysiology
- Clinical manifestations
- Diagnosis
- Treatment
- Peroral Endoscopic Myotomy (POEM)



Definition

- **Mamometrically** characterized by insufficient relaxation of LES and loss of peristalsis. **Radiographically** characterized by aperistalsis, esophageal dilatation, with minimal LES opening, "bird-beak" appearance, poor emptying of barium. **Endoscopically** characterized by dilated esophagus with retained saliva, liquid, undigested food particles in the absence of mucosal stricturing or tumor.

Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol 2013;108:1238-49; quiz 50.

Table 4 The Chicago Classification of esophageal motility v3.0

Achalasia and EGJ outflow obstruction	Criteria
Type I achalasia (classic achalasia)	Elevated median IRP ($>15 \text{ mmHg}^*$), 100% failed peristalsis (DCI $<100 \text{ mmHg}\cdot\text{s}\cdot\text{cm}$) <i>Premature contractions with DCI values less than 450 mmHg·s·cm satisfy criteria for failed peristalsis</i>
Type II achalasia (with esophageal compression)	Elevated median IRP ($>15 \text{ mmHg}^*$), 100% failed peristalsis, panesophageal pressurization with $\geq 20\%$ of swallows <i>Contractions may be masked by esophageal pressurization and DCI should not be calculated</i>
Type III achalasia (spastic achalasia)	Elevated median IRP ($>15 \text{ mmHg}^*$), no normal peristalsis, premature (spastic) contractions with DCI $>450 \text{ mmHg}\cdot\text{s}\cdot\text{cm}$ with $\geq 20\%$ of swallows <i>May be mixed with panesophageal pressurization</i>
EGJ outflow obstruction	Elevated median IRP ($>15 \text{ mmHg}^*$), sufficient evidence of peristalsis such that criteria for types I-III achalasia are not met†

Epidemiology

- M:F = 1:1




Fig. 1. Age distribution of patients with achalasia identified between 2007 and 2011 (n = 3,105).

Table 3. Published studies addressing the incidence and prevalence of achalasia

Study population	No. of cases	Study period	Incidence (cases/100,000/yr)	Prevalence (cases/100,000)
USA				
Rochester (28)	11		0.6	
Virginia (8)	30		0.6	
UK				
Scotland (17)	699		1.1/1.2*	11.2
Oxford (17)	216		0.9/0.9*	9.99
Cardiff (29)	48	1926-1977	0.4	
Nottingham (30)	53	1966-1983	0.5	8
Edinburgh (7)	25	1986-1991	0.8	
Leicester (31)	14	1986-2005	0.89	
Israel (32)	162	1973-1978	0.8	7.9-12.6
New Zealand (6)	152	1980-1984	1.0	
Zimbabwe (33)	25	1974-1983	0.03	
Singapore (4)	49	1989-1996	0.3	1.8
Iceland (9)	62	1952-2002	0.55	8.7
Canada (3)	463	1995-2008	1.63	10.82
Korea	3,105	2007-2011	0.39	7.8

Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. *Am J Gastroenterol* 2013;108:1238-49; quiz 50.

Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. *Gastroenterology* 2010;139:369-74.

Kim E, Lee H, Jung HK et al. Achalasia in Korea: an epidemiologic study using a national healthcare database. *J Korean Med Sci* 2014;29:576-80.

Etiology

- Ganglion cell degeneration due to unclear etiology
 - Autoimmune processes
(e.g., Myenteric antiplexus antibodies, Anti-Hu Ab)
 - Genetic abnormalities
(e.g., Abnormal VIP receptor 1 gene, All-grove's Synd.)
 - Viral infection
(e.g., HSV-1)
 - Neurodegenerative process
- Secondary process
(e.g., Malignancy, Amyloidosis, T.cruzi)

Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology 2010;139:369-74.

Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol


2013;108:1238-49; quiz 50.

Pathophysiology

- Loss of ganglion cell in esophageal myenteric plexus
- Loss of inhibitory neurotransmitter (e.g., NO, VIP)
- Imbalance between excitatory and inhibitory neuron
 - Incomplete LES relaxation
 - Aperistalsis

Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol 2013;108:1238-49; quiz 50.
Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology 2010;139:369-74.

Pathophysiology



Gyawali CP. Achalasia: new perspectives on an old disease. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2016;28(1):4-11.

Clinical manifestations


- Dysphagia
 - Often for both solids and liquids
- Chest pain
 - Substernal pain
 - Unresponsive to reflux therapy
- Heartburn
- Regurgitation
- Weight loss

Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol 2013;108:1238-49; quiz 50.
Francis DL, Katzka DA. Achalasia: update on the disease and its treatment. Gastroenterology 2010;139:369-74.



Imaging study

- Timed-barium esophagogram (TBE)



Neyaz Z, Gupta M, Ghoshal UC. How to perform and interpret timed barium esophagogram. Journal of neurogastroenterology and motility. 2013;19(2):251-256.

Imaging study

- Esophageal high-resolution manometry (HRM)
 - Aperistalsis
 - Incomplete LES relaxation
 - Others
 - Increased basal LES pressure
 - Elevated baseline esophageal body pressure
 - Simultaneous non-propagating contractions

Imaging study

Table 2. Comparison of manometric abnormalities in conventional and high-resolution manometry


Manometric features of achalasia	Conventional manometry Line tracing format	High-resolution manometry Esophageal pressure topography
<i>LES</i>		
	<i>Impaired LES relaxation^a</i> <ul style="list-style-type: none">Mean swallow induced fall in resting LES pressure to a nadir value of >8 mm Hg above gastric pressureComplete relaxation to gastric baseline with a short duration (<6 s)^b <i>Basal pressure^b</i> <ul style="list-style-type: none">>45 mm Hg	<i>Impaired EGJ relaxation</i> <ul style="list-style-type: none">Mean 4 s IRP ≥10 mm Hg over test swallows^a
<i>Esophageal peristalsis</i>	<i>Aperistalsis in distal 2/3 of the esophagus</i> <ul style="list-style-type: none">No apparent contractionsSimultaneous contractions with amplitudes <40 mm Hg	<i>Aperistalsis</i> <ul style="list-style-type: none">Absent peristalsis (type I)Pan-esophageal pressurization (type II)
<i>Atypical/variants</i>	<i>Vigorous</i> <ul style="list-style-type: none">Preserved peristalsis with esophageal contractions >40 mm HgSimultaneous contractions >40 mm Hg<ul style="list-style-type: none">-Isobaric-Nonisobaric	<ul style="list-style-type: none">Spastic achalasia (type III)

EGJ, esophagogastric junction; IRP, integrated relaxation pressure; LES, lower esophageal sphincter.





^aRequired for diagnosis.

^bSupportive for the diagnosis.


Imaging study



Imaging study



Imaging study




Achalasia subgroup	LES		Distal (smooth muscle) esophagus		
	Inhibitory	Excitatory	Circular muscle inhibitory	Circular muscle excitatory	Longitudinal muscle excitatory
Type I (classic)	--	--	--	--	-- to -
Type II (with compression)	-	- to ++	-	-	+ to ++
Type III (spastic)	-	+ to ++	-	+ to ++	+ to ++
EGJ outflow obstruction ^a	-	- to ++	- to +	- to ++	+ to ++


SOURCE: MURRAY S, MELZAK R, PAPKOFF H, TROTTER JH, ABREU R, RABSON AS, LARSON J. PRINCIPLES OF INTERNAL MEDICINE, 18th EDITION: www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

mmHg



- **A: Classic**
 - minimal peristalsis in esophagus



- **C: spastic achalasia**
 - spastic esophageal contractions observed via manometry

Differential diagnosis

- GERD
- Pseudoachalasia (e.g., Cardia cancer, Infiltrating tumor)
- Secondary achalasia
 - Chagas disease
 - Fundoplication
 - Gastric banding


Treatment

- Medications
 - Nitrates, CCB, NO donors (e.g., sildenafil)
 - Others (e.g., anticholinergics, β -blockers, theophylline)

Medication	Efficacy
CCB	<ul style="list-style-type: none">- Symptom improvement (0 ~ 75%)- LES pressure decrease (13 ~ 49%)- Nifedipine 10 ~ 30mg (30 ~ 45mins before meals)
Nitrates	<ul style="list-style-type: none">- Symptom improvement (53 ~ 87%)- LES pressure decrease (30 ~ 65%)- Isosorbide dinitrate 5mg (10 ~ 15mins before meals)


Treatment

- Endoscopic treatment
 - Endoscopic botulinum toxin injection (EBTI)



© 2004 Jane Oliver

BTX blocks pre-synaptic receptors and prevents release of ACH




- Endoscopic pneumatic balloon dilatation
- Peroral endoscopic myotomy (POEM)

Treatment

Review: Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia

Comparison: 1 Pneumatic dilation versus botulinum toxin injection


Outcome: 3 Remission at six months



Review: Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia

Comparison: 1 Pneumatic dilation versus botulinum toxin injection

Outcome: 4 Remission at twelve months



Treatment

- Surgery
 - Heller's myotomy

Surgical Myotomy (Heller's)





Figure 4 Laparoscopic Heller myotomy with partial fundoplication (Dor procedure).




Figure 6 Laparoscopic Heller myotomy with anterior partial fundoplication (Dor procedure). The second and third stitches in the first row incorporate only the fundus and the left side of the esophageal wall.





Figure 7 Laparoscopic Heller myotomy with anterior partial fundoplication (Dor procedure). The uppermost stitch in the second row incorporates the fundus, the esophageal wall, and the right crus.

- Poor response predictor : MegAESOPHAGUS
- Complications : Reflux esophagitis ± Stricture
Barrett's esophagus

Algorithm




EGJ Distensibility Index (EGJ-DI)


Distensibility Index =

EGJ cross-sectional area

Intra-balloon Pressure



Pre-op: 1.1 mm^2/mmHg



Post-POEM: 6.4 mm^2/mmHg 4

NOTES

- Nephrectomy and Natural Orifice Translumenal Endosurgery (NOTES): Transvaginal, Transgastric, Transrectal, and Transvesical Approaches
- Natural orifice transluminal endoscopic drainage for pancreatic abscesses

Peroral endoscopic myotomy (POEM) for esophageal achalasia*

initial experience

Original article


Transgastric hybrid cholecystectomy

Original article


Transvesical Peritoneoscopy: Initial Clinical Evaluation of the Bladder as a Portal for Natural Orifice Translumenal Endoscopic Surgery

Peroral endoscopic myotomy (POEM)

- Hybrid techniques with endoscopic approach
 - Natural orifice transluminal endoscopic surgery (NOTES)



Peroral endoscopic myotomy (POEM)



Li QL, Zhou PH. Perspective on peroral endoscopic myotomy for achalasia: Zhongshan experience. *Gut and liver*. 2015;9(2):152-158.

Advantages of POEM over HM

Peroral Esophageal Myotomy Versus Laparoscopic Heller's Myotomy for Achalasia: A Meta-analysis.

Wei M, Yang T, Yang X, Wang Z, Zhou Z.J Laparoendosc Adv Surg Tech A. 2015 Feb;25(2):123-9.

- ▶ 4 studies compared the outcomes between POEM and LHM. All studies were from the United States and published in 2013. POEM was associated with **comparable complications** (odds ratio [OR]=1.17, 95% [CI] 0.53-2.56, P=.70), **gastroesophageal reflux** (OR=1.00, 95% CI 0.38-2.61, P=1.00), and **symptomatic recurrence by Eckardt score** (OR=0.24, 95% CI 0.04-1.55, P=.13). Other outcomes including pain score, operating time, and hospital stay were assessed with no significant difference between POEM and LHM.

Complications

Table 2. Complications of Peroral Endoscopic Myotomy

Common complications

Mucosal injury

Gas-related complications (intraoperative and postoperative)

Subcutaneous emphysema

Pneumomediastinum

Pneumothorax

Pneumoperitoneum

Pleural effusion

Pneumonitis

Fever (temperature $\geq 38^{\circ}\text{C}$)

Severe postoperative pain

Rare complications

Delay bleeding

Submucosal infection

Gastrointestinal tract leakage

Learning curve

Introducing per-oral endoscopic myotomy (POEM) into clinical practice: defining the learning curve.


Kurian, Swanstrom, Dunst, Bhayani
Gastrointest Endosc, 2012. [in press]

- ▶ 48 POEM cases
- ▶ Gradual transition of procedures to advanced endocopy fellows
- ▶ Time and technical errors as outcomes markers
- ▶ Time and error plateaued after **20 cases** for both faculty and fellows

Table 1: Distribution of LOP and Mucosotomy

Groups	Patients	LOP per cm myotomy	No of mucosotomy
1	1 to 8	16.1 ± 4	8
2	9 to 16	17.2 ± 5	6
3	17 to 24	13.5 ± 3	4
4	25 to 32	15.2 ± 2	0
5	33 to 40	13.2 ± 4	1

Attending Primary
Transition
Fellow Primary



Outcomes of POEM

Table 4. Treatment Outcomes: Eckardt score, Lower Esophageal Sphincter Pressure, and Reflux Esophagitis

Variable	Before POEM	2 mo after POEM	1–2 y after POEM	3 y after POEM	p Value for change at 3 y
Eckardt score, median (range)	6 (5–8)	1 (0–2)	1 (1–2)	1 (1–2)	<0.0001
LES pressure, mmHg, median (range)	25.4 (18.2–35.3)	13.4 (10.5–16.4)	11.9 (7.0–15.9)	11.7 (9.6–14.9)	<0.0001
Endoscopic reflux esophagitis findings, n		LA-A, 140; LA-B, 107; LA-C, 20; LA-D, 1 (follow-up data from 414 patients, 64.7%)	LA-A, 68; LA-B, 25; LA-C, 15; LA-D, 5 (follow-up data from 191 patients, 59.2%)	LA-A, 7; LA-B, 1; LA-C, 1 (follow-up data from 16 patients, 56.3%)	
GERD symptoms		71 (follow-up data from 423, 16.8%)	56 (follow-up data from 289, 19.4%)	13 (follow-up data from 61, 21.3%)	
Prescription of proton pump inhibitor, n (%)		17 (4.0)			
Efficacy		386/423 (91%)	260/286 (91%)	54/61 (88%)	

Establishment of standards protocol

- Incision site (**Anterior wall** VS **posterior wall** VS **GC**)
- Myotomy depth (**Circular muscle layer** VS **Full thickness**)
- Devices (**TT knife** VS **Hybrid knife**)
- Closure methods (**Clip** VS **Suture**)

	Full thickness	Circular muscle	p
Mean operation time, min	41.7 ± 18.9	48.9 ± 28.6	0.020
Intra-operation complications			
Mucosal injury, n (%)	13 (12.6)	27 (20.6)	0.110
Subcutaneous emphysema , n (%)	8 (7.8)	29 (21.1)	0.000
Post-operation complication			
Pneumoperitoneum, n (%)	1 (1.0)	1 (0.8)	1.000
Pneumonia, n (%)	41 (48.8)	91 (54.5)	0.430
Length of postoperative HD	2.7 ± 1.1	3.6 ± 2.7	0.000
Eckardt score			
Δ value	6.5 ± 2.3	7.0 ± 2.2	0.110
Treatment success (< 3), n (%)	95 (96.0)	115 (95.0)	0.750
LES pressure improvement (Δ value)	18.1 ± 13.9	17.4 ± 10.2	0.750

Li QL, Chen WF, Zhou PH, et al. Peroral endoscopic myotomy for the treatment of achalasia:

a clinical comparative study of endoscopic full-thickness and circular muscle myotomy. Journal of the American College of Surgeons. 2013;217(3):442-451.

Stavros Stavropoulos, Per Oral Endoscopic Myotomy : Technique and Outcomes DDW 2016

Recommendation

Recommendation

1. Achalasia must be suspected in those with dysphagia to solids and liquids and in those with regurgitation unresponsive to an adequate trial of proton pump inhibitor (PPI) therapy (strong recommendation, low-quality evidence).

Recommendations

1. All patients with suspected achalasia who do not have evidence of a mechanical obstruction on endoscopy or esophagram should undergo esophageal motility testing before a diagnosis of achalasia can be confirmed (strong recommendation, low-quality evidence).
2. The diagnosis of achalasia is supported by esophagram findings including dilation of the esophagus, a narrow esophagogastric junction with “bird-beak” appearance, aperistalsis, and poor emptying of barium (strong recommendation, moderate-quality evidence).
3. Barium esophagram is recommended to assess esophageal emptying and esophagogastric junction morphology in those with equivocal motility testing (strong recommendation, low-quality evidence).
4. Endoscopic assessment of the gastroesophageal junction and gastric cardia is recommended in all patients with achalasia to rule out pseudoachalasia (strong recommendation, moderate-quality evidence).

Recommendation

Recommendations

1. Either graded pneumatic dilation (PD) or laparoscopic surgical myotomy with a partial fundoplication are recommended as initial therapy for the treatment of achalasia in those fit and willing to undergo surgery (strong recommendation, moderate-quality evidence).
2. PD and surgical myotomy should be performed in high-volume centers of excellence (strong recommendation, low-quality evidence).
3. The choice of initial therapy should be guided by patients' age, gender, preference, and local institutional expertise (weak recommendation, low-quality evidence).
4. Botulinum toxin therapy is recommended in patients who are not good candidates for more definitive therapy with PD or surgical myotomy (strong recommendation, moderate-quality evidence).
5. Pharmacologic therapy for achalasia is recommended for patients who are unwilling or cannot undergo definitive treatment with either PD or surgical myotomy and have failed botulinum toxin therapy (strong recommendation, low-quality evidence).

Thank you for attention